Silvia Solymosyova, a 17-year-old artistic swimmer and dancer from Slovakia, has gone viral on TikTok for these insane underwater moves
Silvia Solymosyova, a 17-year-old artistic swimmer and dancer from Slovakia, has gone viral on TikTok for these insane underwater moves
On May 17, 2007, Jonathan Sackler, who has since passed away, emailed relatives and a financial advisor, triggering an anxious discussion, according to settlement documents U.S. prosecutors disclosed on Wednesday. Between 2008 and 2019, Purdue transferred more than $10 billion, including roughly $4 billion in cash to Sackler-controlled entities, according to filings. Family members on Wednesday said the transfers were proper and that documents scheduled to be released in the future would support that claim.
Argo Group Announces Estimated Losses from Third Quarter 2020 Catastrophes
Stocks traded choppily before ending lower, as investors considered whether lawmakers would manage to pass a stimulus package sometime this week.
Xperi Holding Corporation (Nasdaq: XPER), ("Xperi" or the "Company") will announce its financial results for the third quarter ended September 30, 2020, on Monday, November 9, 2020, following the close of the market. The Company will host an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) that same day.
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR) first virtual annual meeting, ACR Convergence 2020. The event is being held online from November 5-9, 2020. Exagen’s Chief Scientific Officer, Anja Kammesheidt, shared, “Exagen is honored to have had the opportunity to partner with such great collaborators on this year’s abstracts. Our clinical research and development teams are committed to advancing the understanding of the role of cell-bound complement activation products (CB-CAPs) in lupus. We are pleased to be sharing these data at this year’s virtual ACR event.”Below is the list of accepted abstracts along with links to each:Saturday, November 7thPoster Presentation | Presented by Michelle Petri, MD | Abstract 0857 Title: Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory Session Title: SLE – Treatment Poster I Session Time: 9:00 am – 11:00 am ESTSunday, November 8thOral Presentation | Presented by Yevgeniya Gartshteyn, MD | Abstract 1510 Title: Platelet-bound C4d is Associated with Platelet Activation and Arterial Thrombotic Events Session Title: SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511) Session Time: 3:00 pm – 3:50 pm ESTOral Presentation | Presented by Michelle Petri, MD | Abstract 1513 Title: Role of Platelet C4d in Thrombosis and Lupus Nephritis Session Title: SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516) Session Time: 4:00 pm – 4:50 pm ESTMonday, November 9th Poster Presentation | Presented by Yevgeniya Gartshteyn, MD | Abstract 1792 Title: Platelet-bound C4d is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside Session Time: 9:00 am – 11:00 am ESTPoster Presentation | Presented by Rosalind Ramsey-Goldman, MD | Abstract 1797 Title: A Multianalyte Assay Panel (MAP) With Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA And Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside Session Time: 9:00 am – 11:00 am ESTPoster Presentation | Presented by Jill Buyon, MD | Abstract 1808 Title: Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE) Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside Session Time: 9:00 am – 11:00 am EST* Abstracts will remain live until March 11, 2021About Exagen Inc.Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visit www.Exagen.com Forward Looking StatementsExagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE® test. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; third party payers not providing coverage and adequate reimbursement for the company’s testing products or promoted therapeutics; the company’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the company’s business; risks associated with maintaining third-party partnerships and Exagen’s performance thereunder; and other risks described in the company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Investors Westwicke Partners Mike Cavanaugh Mike.Cavanaugh@westwicke.com 646.677.1838Company Exagen Inc. Kamal Adawi, Chief Financial Officer firstname.lastname@example.org 760.477.5514
ATHENS, Greece, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Capital Product Partners L.P. (NASDAQ: CPLP) today announced that its board of directors has declared a cash distribution of $0.10 per common unit for the third quarter of 2020 ended September 30, 2020. The third quarter common unit cash distribution will be paid on November 10, 2020 to common unit holders of record on November 2, 2020.About Capital Product Partners L.P.Capital Product Partners L.P. (NASDAQ: CPLP), a Marshall Islands master limited partnership, is an international owner of ocean-going vessels. CPLP currently owns 14 vessels, including 13 neo panamax container vessels and one capesize bulk carrier.For more information about the Partnership, please visit: www.capitalpplp.com.Forward-Looking Statements The statements in this press release that are not historical facts may be forward-looking statements (as such term is defined in Section 21E of the Securities Exchange Act of 1934, as amended). These forward-looking statements involve risks and uncertainties that could cause the stated or forecasted results to be materially different from those anticipated. Unless required by law, we expressly disclaim any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in our views or expectations, to conform them to actual results or otherwise. We assume no responsibility for the accuracy and completeness of the forward-looking statements. We make no prediction or statement about the performance of our common units.CPLP-FContact Details:Capital GP L.L.C. Jerry Kalogiratos CEO Tel. +30 (210) 4584 950 E-mail: email@example.comCapital GP L.L.C. Nikos Kalapotharakos CFO Tel. +30 (210) 4584 950 E-mail: firstname.lastname@example.orgInvestor Relations / Media Nicolas Bornozis Capital Link, Inc. (New York) Tel. +1-212-661-7566 E-mail: email@example.comSource: Capital Product Partners L.P.
Reynolds Consumer Products Inc. (Nasdaq: REYN)(the "Company"), announced today it will report results for the third quarter ended September 30, 2020, on Wednesday, November 11, 2020, after market close.
Limestone Bancorp, Inc. (NASDAQ: LMST) ("the Company"), parent company of Limestone Bank ("the Bank"), today reported unaudited results for the third quarter of 2020. Net income available to common shareholders for the third quarter of 2020 was $2.1 million, or $0.28 per basic and diluted common share, compared with $2.3 million, or $0.31 per basic and diluted share, for the third quarter of 2019. Net income for the nine months ended September 30, 2020, was $5.9 million, or $0.79 per diluted common share, compared with net income of $8.8 million, or $1.17 per diluted share, for the nine months ended September 30, 2019.
MALVERN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 third quarter financial results on November 11, 2020. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (855) 548-1219 for participants in the U.S. or Canada and (409) 217-8881 for international callers, using conference ID 1670209. A live and archived webcast of the event can be accessed via the Events & Presentations page of the investor section of TELA's website.About TELA Bio, Inc. TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing, and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA Bio's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA Bio's portfolio is supported by quality, data-driven science, and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.TELA Bio Contact Stuart Henderson Vice President, Corporate Development and Investor Relations TELA Bio, Inc. 484-320-2930 Investor Contact Greg Chodaczek 347-620-7010 firstname.lastname@example.org
Conference Call to Discuss Results on November 5, 2020 at 8:00 a.m. ETWARSAW, Ind., Oct. 21, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today that the Company is scheduled to release its third quarter 2020 financial results on Wednesday, November 4, 2020, after the market closes. OrthoPediatrics will host a conference call on Thursday, November 5, 2020, at 8:00 a.m. ET to discuss the results. The dial-in numbers are (855) 289-4603 for domestic callers and (614) 999-9389 for international callers. The conference ID number is 5038238. A live webcast and replay of the conference call will be available online from the investor relations page of the OrthoPediatrics’ corporate website at www.orthopediatrics.com.About OrthoPediatrics Corp. Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 35 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States. For more information, please visit www.orthopediatrics.com.Investor Contact The Ruth Group Jan Medina, CFA (646) 536-7035 email@example.com
Laird Superfood, Inc. (NYSE American: LSF) will report financial results for the third quarter ended September 30, 2020 on Thursday, November 12, 2020 after market close. Laird Superfood will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the results.
CINCINNATI, Oct. 21, 2020 (GLOBE NEWSWIRE) -- The Hillman Companies, Inc. (NYSE-Amex: HLM.PR) (the "Company" or "Hillman”) today announced it plans to host a conference call to discuss the financial results for the quarter ended September 26, 2020 on Monday, October 26, 2020, at 4:00pm EDT. Participants may join the call by dialing 1-(866) 673-2033 a few minutes before the call start time. Participants should refer to conference ID – 5142215. A live audio webcast of the conference call will also be available in a listen-only mode on the company's website, which is located at http://www.hillmangroup.com/investor/relations/quarterly-results. Participants who want to access the webcast should visit the company's website about five minutes before the call. The archived webcast will be available for replay on the company's website after the call.Founded in 1964 and headquartered in Cincinnati, Ohio, Hillman is a leading North American provider of complete hardware solutions, delivered with industry best customer service to over 38,000 customers. Hillman designs innovative product and merchandising solutions for complex categories that deliver an outstanding customer experience to home improvement centers, mass merchants, national and regional hardware stores, pet supply stores, and OEM & Industrial customers. Leveraging a world-class distribution and sales network, Hillman delivers a “small business” experience with “big business” efficiency.For more information about the Company, please visit our website at http://www.hillmangroup.com or call Investor Relations at (513) 851-4900 ext. 68281
Eden Prairie, Minn., Oct. 21, 2020 (GLOBE NEWSWIRE) -- NVE Corporation (Nasdaq: NVEC) announced today financial results for the quarter and six months ended September 30, 2020. Total revenue for the second quarter of fiscal 2021 decreased 33% to $4.38 million from $6.50 million for the the prior-year quarter. The decrease was due to a 33% decrease in product sales and a 29% decrease in contract research and development revenue. Net income for the second quarter of fiscal 2021 decreased 42% to $2.22 million, or $0.46 per diluted share, compared to $3.82 million, or $0.79 per share, for the prior-year quarter. For the first six months of fiscal 2021, total revenue decreased 30% to $8.97 million from $12.8 million for the first six months of the prior year. The decrease was due to a 31% decrease in product sales and a 14% decrease in contract research and development revenue. Net income decreased 38% to $4.63 million, or $0.96 per diluted share, compared to $7.43 million, or $1.53 per share, for the first half of fiscal 2020. The company also announced a quarterly cash dividend to shareholders of $1.00 per share of common stock, payable November 30, 2020 to shareholders of record as of November 2, 2020. “We are pleased to report a solid profit for the quarter despite a significant impact from COVID-19 pandemic on our revenue,” said NVE President and Chief Executive Officer Daniel A. Baker, Ph.D. NVE is a leader in the practical commercialization of spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store and transmit information. The company manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. Statements used in this press release that relate to future plans, events, financial results or performance are forward-looking statements that are subject to certain risks and uncertainties including, among others, such factors as risks and uncertainties related to future sales and revenues, risks related to the COVID-19 pandemic, risks and uncertainties related to future dividend payments and stock repurchases, as well as the risk factors listed from time to time in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended March 31, 2020 as updated in our Quarterly Reports on Form 10-Q for the quarters ended June 30 and September 30, 2020, and other reports filed with the SEC. NVE CORPORATION STATEMENTS OF INCOME QUARTERS AND SIX MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 (Unaudited) Quarter Ended Sept. 30 2020 2019 Revenue Product sales$4,159,173 $6,187,708 Contract research and development221,612 314,237 Total revenue 4,380,785 6,501,945 Cost of sales941,287 1,346,098 Gross profit 3,439,498 5,155,847 Expenses Research and development 815,965 926,596 Selling, general, and administrative358,182 368,450 Total expenses1,174,147 1,295,046 Income from operations 2,265,351 3,860,801 Interest income401,392 456,309 Income before taxes 2,666,743 4,317,110 Provision for income taxes444,403 495,048 Net income$2,222,340 $3,822,062 Net income per share – basic$0.46 $0.79 Net income per share – diluted$0.46 $0.79 Cash dividends declared per common share$1.00 $1.00 Weighted average shares outstanding Basic 4,834,709 4,846,010 Diluted 4,834,809 4,847,881 Six Months Ended Sept. 30 2020 2019 Revenue Product sales$8,517,808 $12,273,072 Contract research and development452,239 523,569 Total revenue 8,970,047 12,796,641 Cost of sales1,777,709 2,438,135 Gross profit 7,192,338 10,358,506 Expenses Research and development 1,696,948 1,899,663 Selling, general, and administrative713,193 698,459 Total expenses2,410,141 2,598,122 Income from operations 4,782,197 7,760,384 Interest income800,604 915,348 Income before taxes 5,582,801 8,675,732 Provision for income taxes948,596 1,246,251 Net income$4,634,205 $7,429,481 Net income per share – basic$0.96 $1.53 Net income per share – diluted$0.96 $1.53 Cash dividends declared per common share$2.00 $2.00 Weighted average shares outstanding Basic 4,834,872 4,846,010 Diluted 4,834,986 4,849,357 NVE CORPORATION BALANCE SHEETS SEPTEMBER 30 AND MARCH 31, 2020 (Unaudited) Sept. 30, 2020 March 31, 2020 ASSETS Current assets Cash and cash equivalents$3,845,070 $8,065,594 Marketable securities, short-term 23,231,981 19,084,814 Accounts receivable, net of allowance for uncollectible accounts of $15,000 1,922,076 2,694,018 Inventories 3,928,524 3,884,450 Prepaid expenses and other assets610,635 655,835 Total current assets 33,538,286 34,384,711 Fixed assets Machinery and equipment 9,280,062 9,280,062 Leasehold improvements1,797,245 1,797,245 11,077,307 11,077,307 Less accumulated depreciation and amortization 10,648,191 10,494,840 Net fixed assets 429,116 582,467 Deferred tax assets- 108,119 Marketable securities, long-term40,777,322 43,606,495 Right-of-use asset – operating lease752,861 816,358 Total assets$75,497,585 $79,498,150 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities Accounts payable$154,566 $186,993 Accrued payroll and other424,957 482,074 Operating lease113,666 127,134 Total current liabilities 693,189 796,201 Deferred tax liabilities 141,990 - Operating lease644,987 706,600 Total liabilities1,480,166 1,502,801 Shareholders’ equity Common stock 48,332 48,350 Additional paid-in capital 19,329,577 19,383,956 Accumulated other comprehensive income 1,628,861 516,523 Retained earnings53,010,649 58,046,520 Total shareholders’ equity74,017,419 77,995,349 Total liabilities and shareholders’ equity$75,497,585 $79,498,150 CONTACT: Curt Reynders (Chief Financial Officer), 952-829-9217
DAYTONA BEACH, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) announced today that its Board of Directors has authorized, and the Company has declared, an increase in the Company’s quarterly cash dividend to $0.22 per share of common stock for the fourth quarter of 2020 from its previous quarterly cash dividend of $0.20 per share of common stock. The dividend is payable on December 31, 2020 to stockholders of record as of the close of business on December 15, 2020. The 2020 fourth quarter cash dividend represents a 10.0% increase over the Company’s previous quarterly dividend and an annualized yield of approximately 6.1% based on the closing price of the common stock on October 20, 2020. About Alpine Income Property Trust, Inc.Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that acquires, owns and operates a portfolio of high-quality single-tenant net leased commercial income properties.We encourage you to review our most recent investor presentation which is available on our website at http://www.alpinereit.com.SAFE HARBORThis press release may contain “forward-looking statements.” Forward-looking statements include statements that may be identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company’s current expectations and assumptions regarding capital market conditions, the Company’s business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, the Company’s actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include general business and economic conditions, continued volatility and uncertainty in the credit markets and broader financial markets, risks inherent in the real estate business, including tenant defaults, potential liability relating to environmental matters, illiquidity of real estate investments and potential damages from natural disasters, the impact of the COVID-19 Pandemic on the Company’s business and the business of its tenants and the impact on the U.S. economy and market conditions generally, other factors affecting the Company’s business or the business of its tenants that are beyond the control of the Company or its tenants, and the factors set forth under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.Contact:Matthew M. Partridge Senior Vice President, Chief Financial Officer & Treasurer (386) 944-5643 firstname.lastname@example.org
NETGEAR, Inc. (NASDAQ: NTGR), a global networking company that delivers innovative networking and Internet connected products to consumers and businesses, today reported financial results for the third quarter ended September 27, 2020.
PEARL RIVER, N.Y., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Sterling Bancorp (NYSE: STL), the parent company of Sterling National Bank, today announced that the Board of Directors has declared a quarterly cash dividend of $0.07 per share. The dividend is payable November 16, 2020 to holders of record as of November 2, 2020. About Sterling Bancorp Sterling Bancorp, whose principal subsidiary is Sterling National Bank, specializes in the delivery of service and solutions to business owners, their families and consumers within the communities we serve through teams of dedicated and experienced relationship managers. Sterling National Bank offers a complete line of commercial, business, and consumer banking products and services. For more information, visit the Sterling Bancorp website at www.sterlingbancorp.com.STERLING BANCORP CONTACT: Emlen Harmon, SVP – Director of Investor Relations 212.309.7646Sterling Bancorp Two Blue Hill Plaza, Second Floor Pearl River, NY 10965T 845.369.8040 F 845.369.8255http://www.sterlingbancorp.com
System designed to alleviate pain and restore function and mobility of the wrist jointBEDFORD, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company’s WristMotion Total Arthroplasty System received 510(k) clearance from the U.S. Food and Drug Administration. The WristMotion Total Arthroplasty System is indicated for replacement of the painful wrist joint due to rheumatoid arthritis, osteoarthritis, or post-traumatic arthritis. “We are delighted to receive clearance for this innovative wrist device as it is another step forward in our mission to provide motion preserving technologies. This is an underserved market and our solution is in response to demand from both orthopedic surgeons and patients for solutions that avoid fusion and preserve as much natural motion and anatomy as possible,” said Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika. “For Anika, this is another new product category coming from our recently acquired Arthrosurface business, which has a storied history of introducing orthopedic innovations that are minimally invasive, bone-sparing, and motion preserving. All too often, painful wrists caused by arthritis or trauma are treated by fusing the joint. We want to provide alternatives to that outcome that preserve joint motion for the patient. While fusions alleviate pain, the loss of motion in a wrist can be quite life changing, perhaps more than patients initially realize. Anika is committed to doing all that we can to allow patients to remain active and truly live life to the fullest.”The WristMotion Total Arthroplasty System is a modular joint restoration system that replaces both the radial and carpal portions of the joint. The system is unique in that it combines the patented and proven fixation and dual curvature implant geometries with a unique instrumentation system that allows for precise implant placement and joint tensioning. A design philosophy for the system was to preserve the complex kinematics of the joint, often referred to as the ‘dart throwers’ motion.“With new kinematic information on implant design and function, the anatomic WristMotion Total Arthroplasty System utilizes an innovative articulating design for greater range of motion in both flexion/extension and radial/ulnar deviation. The WristMotion platform also allows intraoperative decision making with regards to performing a hemi or total arthroplasty to treat all stages of wrist arthritis. The R&D team worked extremely hard to design this new solution for wrist arthritis and I’m thrilled to see this device come to market and benefit patients,” said Arnold-Peter C. Weiss, M.D., Chief - Hand, Upper Extremity & Microvascular Surgery, Vice Chairman and Professor of Orthopaedics, Warren Alpert Medical School, Brown University. With over 30 years of clinical experience in total wrist arthroplasty, Dr. Weiss provided his expertise as the lead surgeon designer of the WristMotion Total Arthroplasty System.The 510(k) clearance for the WristMotion system triggers a one-time $5 million earnout payment as a result of the achievement of a regulatory milestone set forth in the merger agreement executed among Anika and Arthrosurface, Incorporated on January 4, 2020. This earnout payment will be paid in the fourth quarter of 2020.About Anika Therapeutics, Inc.Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit www.anika.com.Forward-Looking StatementsThis press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact. These statements may include, but are not limited to, those relating to the potential market for, and revenue growth opportunity for the Company associated with, this product. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company's ability to provide an adequate and timely supply of its products to its customers; and (x) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.For Investor Inquiries: Anika Therapeutics, Inc. Kristen Galfetti, 781-457-9000 Executive Director, Investor Relations email@example.com For Media Inquiries: W2O Group Rachel Girard, 617-379-6760 firstname.lastname@example.org
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2020 financial results before the open of the market on Tuesday, November 3, 2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 1346474, approximately 15 minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.About Oxford ImmunotecOxford Immunotec Global PLC is a global, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world’s largest cause of death from infectious disease. The Company is an experienced manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.CONTACTS:For Media and Investor Inquiries: Matt McLaughlin Chief Financial Officer Oxford Immunotec Tel: +1 (508) 573-9953 email@example.com
Sterling Construction Company, Inc. (NasdaqGS: STRL) ("Sterling" or "the Company") today announced that it plans to issue its financial results for the third quarter of 2020 on Monday, November 2, 2020, after the stock market closes.
Whirlpool Corporation (NYSE: WHR) today reported financial results for the third-quarter of 2020.